Abstract
Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer. This review focuses on its origin, molecular and clinical characteristics, and treatment.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms* / drug therapy
-
Breast Neoplasms* / immunology
-
Breast Neoplasms* / mortality
-
Breast Neoplasms* / pathology
-
Female
-
Genes, BRCA1
-
Humans
-
Mutation
-
Prognosis
-
Receptor, ErbB-2
-
Receptors, Estrogen
-
Receptors, Progesterone
-
Survival Rate
Substances
-
Antineoplastic Agents
-
Receptors, Estrogen
-
Receptors, Progesterone
-
Receptor, ErbB-2